Halladay Benjamin 4

What Happened

• Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics (ESPR), sold 6,424 shares on 2026-03-17 at $2.71 per share, for total proceeds of $17,377. The Form 4 reports the sale as an open market or private sale and includes a footnote stating the shares were sold to satisfy a tax obligation on vested restricted stock units (RSUs). This is a sale (routine tax withholding), not a purchase.

Key Details

• Transaction date: 2026-03-17; Price: $2.71 per share; Shares sold: 6,424; Total proceeds: $17,377.
• Transaction code: S (Sale). Footnote F1: sale to satisfy tax obligation on vested RSUs (tax withholding).
• Filing date: 2026-03-18 (reported promptly on the next day).
• Shares owned after transaction: Not specified in the filing.

Context

• Sales to cover tax obligations on vested RSUs are common and are generally treated as routine administrative transactions rather than directional bets on the stock. The filing indicates this was a tax-related sale; it does not by itself signal a change in the officer's view of the company.